ATC Group: A03AB05 Propantheline

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A03AB05 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A03 Drugs for functional gastrointestinal disorders
4 A03AB Synthetic anticholinergics, quaternary ammonium compounds
5 A03AB05 Propantheline

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 60 mg
PAREN - Parenteral 60 mg

Active ingredients in A03AB05

Active Ingredient Description

Propantheline inhibits parasympathetic activity by blocking the action of the neurohormone, acetylcholine, on the neuroeffector cell. This blocking action of propantheline is instrumental in reducing gastric acid secretion and gastrointestinal motor activity.

Related product monographs

Title Information Source Document Type  
PRO-BANTHINE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Australia (AU)

Japan (JP)

New Zealand (NZ)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.